Edison finds hope in Rett syndrome drug study miss
This article was originally published in Scrip
Executive Summary
Edison Pharmaceuticals' Rett syndrome drug EPI-743 (vatiquinone) has missed its primary endpoint in a Phase II study; but the company reports the drug did have some success in improving a specific symptom of the disease.